PharmaSwiss
History and Milestones

PharmaSwiss was founded in 2000, and at that time operated only in the 6 countries of Ex-Yugoslavia.  Since its founding, the company has been headquartered in Switzerland.  Currently PharmaSwiss operates in 19 markets throughout Central and Eastern Europe, as well as Greece and Israel.

 

Fall, 1999: BMS spins-off ex-Yugoslavia operations, invites 10 year veteran Petr Nemec to set up new company with 22 employees.

 

January 24th, 2000: PharmaSwiss, Joint stock company is incorporated in Zug, Switzerland.  Fully-owned subsidiaries established in Bosnia, Croatia, Serbia, Montenegro, Slovenia and representative office in FYR of Macedonia.

 

2002:  PharmaSwiss signs deals to represent Ferring’s entire portfolio and Fujisawa’s Prograf  in the countries of ex-Yugoslavia plus Albania.

 

2003:  PharmaSwiss designated to represent Ipsen’s portfolio in the countries of ex-Yugoslavia. Read more...

 

2004 PharmaSwiss signs a deal to represent Wyeth in both the Baltics and the countries of ex-Yugoslavia.  PharmaSwiss also signs a deal to represent Eli Lilly in Serbia and Montenegro.  “1st Euro million” of Monopril sales reached in Serbia and Monetnegro. Tazocin (Wyeth) successfully launched in Serbia and Montenegro.  Enbrel (Wyeth) has been launched in Croatia. Enbrel in Slovenia - one of the most prescribed biological drug in Rheumatology . Prograf – highest growth among comparable immunosuppressants launched in Slovenia. Read more...

 

2005: PharmaSwiss opens a subsidiary in Greece and signs a deal to represent BMS’s open market business there.  PharmaSwiss signs a deal to represent Amgen in Serbia and Montenegro.  Prograf (Fujisawa, later Astellas) and Cardiopirin (PharmaSwiss Brand for low dose ASA) launched in Croatia. PharmaSwiss Bosnia and Herzegovina became market leader in IVF protocols with Menopur and Decapeptyl (by Ferring). Tazocin – one of highest market share in EU among broad spectrum lifesaving iv. antibiotics lauched in Slovenia.  Menopur – IVF product from Ferring introduced to Slovenian market. Aloxi (Helsinn) launched in Latvia. Read more...

 

2006:  PharmaSwiss expands to Czech Republic after signing a five year representation deal for BMS’s open market products. BMS also designates PharmaSwiss to manage its entire portfolio in the Baltic states. Tanakan reached sales of € 1 million in Serbia and Montenegro. Tazocin sales rose above € 1 million in Serbia and Montenegro. Prevenar (Wyeth) – pneumococcal conjugate vaccine launched in Croatia.  Prograf is imposed as the first line therapy for kidney transplanted patients in Bosnia and Herzegovina. Humulins (insulins by Ely Lilly) gain 100% market share at Kosovo annual tender for 2007. Read more...

 

2007: PharmaSwiss opens a subsidiary in Israel. Cardiopirin and Monodipin, respectively, achieved sales over Eur 1 million in Serbia and Montenegro. Aloxi (palonosteron) , Rapamune (Wyeth, sirolimus – the novel immunosuppressive drug for kidney transplanted patients) and DicloRapid – PharmaSwiss brand for advanced pharmaceutical formulation of fast acting diclofenac sodium, have been launched in Croatia. Baraclude –  the novel nucleotide analogue indicated in the treatment of chronic hepatitis B (by BMS) launched in Slovenia. Strepsils becomes market leader among many products for sore throat in Macedonia and still shows significant sales growth on annual basis. Fervex - market leader in products for cold & fly treatment at Kosovo.   Read more...

 

2008: PharmaSwiss opens a subsidiary in Bulgaria and Hungary.  PharmaSwiss takes over Wyeth business in Bulgaria. BMS entrusts PharmaSwiss Hellas with the CV Products Karvea & Karvezide and the whole BMS Hellas OTC portfolio including Depon, the bestselling product in Units on the Greek Market. Sales more than triple, to reach a total of 50 + mil under the management and PharmaSwiss Hellas personnel goes up to 79.

Monopril Plus achieves sales of 2.5 million Euro in Serbia and Montenegro. Tanakan reached sales of € 2 million in Serbia and Montenegro. DicloDuo 75 mg capsules of gastro resistant diclofenac sodim pallets – fast and slow release diclofenac in one capsule – launched in Croatia. Prograf (Astellas novel immunosuppressant) gains 100% reimbursement in Albania. Read more...

 

2009: DicloDuo maintains the market leader position of total oral diclofenacs in Serbia and Montenegro with sales over € 5 million. Enbrel reached ~85% of market share in Serbia and close to €4 million of net sales in Serbia and Montenegro. Forteo achieved more than €1 million in sales in the 1st year since launched in Serbia and Montenegro. Cardiopirin is a leader in the LD enteric coated ASA market with sales above Eur 4.5 million in Serbia and Montenegro. Fenolip became the Serbian fibrate market leader with kEur 850 in sales. Monopril became the highest selling pharmaceutical brand in Serbia and Montenegro with Eur 16.5 million sales. Tanakan shows CAGR 42.96% for 2004-2009 period in Serbia and Montenegro. Fenolip (PharmaSwiss brand for novel, advanced formulation of fenofibrate) and Centrum  (worldwide famous multivitamins / multiminerals supplement produced by Whitehall) launched in Croatia. Agreement with Recordati to launch its Lomexin/Gynoxin products in Hungary. Mamavit is best selling  multivitamins product for pregnant and breastfeeding women in Macedonia just 3 years after the product launch. DiclofenacDuo PharmaSwiss is one of the best performing diclofenac brands in Bulgaria.  PharmaSwiss reached 40% of share in tender business of antiinfectives in Albania. Sprycel (BMS) launched and fully reimbursed  in Estonia. PharmaSwiss Israel has successfully launched the SWISS RELIEF line of products against pain: Swiss Relief Spray Gel – Mika Pharma’s  4% diclofenac spray gel was the first in line. Only 1.5 year after the launch product has been listed in all sick funds in Israel (with significant discounts to patients), as well as the big pharmacy chains and private pharmacies. It is already the 2nd biggest product in this category in Israel. Read more...

 

2010: PharmaSwiss takes over the Covidien Medical device business in Greece, marking a key milestone: an expansion from pharmaceuticals / OTCs  / food supplements into another Healthcare sector. 

 

Monopril Plus (fosinopril with diuretic), Sprycel (dasatinib, BMS novel drug used to treat chronic myeloid leukemia and acute lymphoblastic leukemia), Torisel (temsirolimus, Wyeth / Pfizer new therapetical option used to treat renal cell carcinoma) are launched by PharmaSwiss in Croatia. Launch of Fenobrat (PharmaSwiss brand for novel fenofibrate formulation), Counter Pain Umbrella, Physiodose (Gilbert) in Greece.  Ferring products for IVF, represented by PharmaSwiss in Bulgaria are showing continuous progress gaining doctors and patients trust. Ferring human gonadotropin is the best growing product in Bulgaria. Read more...

 

January, 2011: fully operational affiliate to be established in Slovakia

 

 

 PictureLibraryDisplay